Proteon Therapeutics Announces Top-Line Results From Phase 3 PATENCY-2 Clinical Trial of Vonapanitase in Radiocephalic Arteriovenous Fistulas
28 mars 2019 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
13 mars 2019 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 13, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 11th
04 mars 2019 16h30 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Publication of Results from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with Chronic Kidney Disease
24 janv. 2019 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq: PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with...
Proteon Therapeutics to Present at the Stifel 2018 Healthcare Conference November 13th
08 nov. 2018 07h45 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Third Quarter 2018 Financial Results
07 nov. 2018 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at Two Upcoming Investor Conferences
29 août 2018 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq: PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces Second Quarter 2018 Financial Results
07 août 2018 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics to Present at the JMP Securities Life Sciences Conference June 21st
14 juin 2018 08h00 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., June 14, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...
Proteon Therapeutics Announces First Quarter 2018 Financial Results
09 mai 2018 08h10 HE
|
Proteon Therapeutics, Inc.
WALTHAM, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with...